Air Muscle and Task Practice in Upper Limb Stroke Rehab
Air Muscle and Task Practice in Upper Limb Stroke Rehab
Many patients who have sustained strokes are unable to effectively use their hemiparetic
 upper extremity. Limited mobility in the performance of daily activities, such as eating or
 dressing, adversely affects their quality of life and compromises independence.
 Rehabilitation techniques engaging the hemiparetic limb in repetitive task practice (RTP) may
 improve upper extremity function and quality of life in patients with stroke, but costs limit
 the number of patients that can utilize this type of therapy. Advances in microprocessor
 design and function make the use of an assistive device as an adjunct to RTP plausible. An
 innovative assistive repetitive motion (ARM) device using an "air muscle" has been developed
 specifically for the rehabilitation of the hemiparetic upper extremity. The primary aim of
 the proposed study is to collect pilot data to estimate the clinical effectiveness of using
 the ARM device in conjunction with RTP to improve upper extremity motor function and the
 quality of life of patients with stroke. Twenty sub-acute (3 to 9 mos. post-stoke) patients
 will be randomized to a RTP only or ARM + RTP group. The RTP group will receive 15 days (4
 hours per day) of intensive one-on-one RTP therapy. The ARM + RTP group will use the ARM
 device for 2 hours per day and receive 2 hours of intensive RTP per day for 15 days. Clinical
 motor function and quality of life measures will be taken before and after the interventions
 and two months later. We hypothesize that the ARM + RTP group will exhibit greater
 improvements in motor function and quality of life measures than the RTP only group.
Specific Aim 1: Estimate the effectiveness of using an assistive repetitive motion device
 (ARM) in conjunction with repetitive task practice (RTP) on motor recovery of patients with
 sub-acute stroke. This aim will be examined by comparing pre-intervention motor performance
 levels with the immediate post-intervention and two months post-intervention. The primary
 outcome variables will be scores on the Fugl-Meyer Motor Assessment Test (FMA) and Wolf Motor
 Function Test (WMFT). We hypothesize patients in the RTP + ARM group will exhibit greater
 gains in upper extremity motor recovery/performance than the RTP and ARM only groups.

 Specific Aim 2: Estimate the effectiveness of using the ARM device in conjunction with RTP on
 health related quality of life of patients with sub-acute stoke. This aim will be examined
 through the administration of clinical quality of life questionnaires. The primary outcome
 variable to assess health related quality of life will be change scores on the Stroke Impact
 Scale (SIS), controlling for depressed mood as measured by the Center for Epidemiologic
 Studies Depression (CES-D) scale, from the pre-, immediate post and two-month post
 intervention testing sessions. We hypothesize patients in the RTP + ARM group will exhibit
 greater improvements on quality of life measures at the two-month follow-up session than the
 RTP and ARM only groups.

 Study Design, Methods and Procedures:

 Patients will be randomized to one of the following three interventional groups: repetitive
 task practice, assistive repetitive motion and repetitive task practice plus assistive
 repetitive motion. Details regarding the activities each group will perform are below.

 1. Repetitive task practice (RTP) procedure: patients in the RTP group will work closely
 with rehabilitation professional (supervisor) for four hours per day for three weeks. We
 are currently accepting applications for this position. At minimum, this individual will
 be a licensed Physical or Occupational Therapist with clinical experience and a desire
 to participate and follow the outlined research protocol.

 Patients will report to the Mellon Center at the Cleveland Clinic Foundation (CCF)
 around 8:00 AM each day and leave around 12:00 PM. During their stay at the CCF they
 will be asked to engage in a series of activities that are planned for them to use their
 weaker or more impaired hand and arm. We will be making some additional measures about
 the speed at which they can do functional activities (such as reaching and folding a
 towel) during the testing days immediately before and after the training period and two
 months after completion of the training (e.g. Wolf Motor Function Test (WMFT) and
 Fugl-Meyer Motor Assessment (FMA)). Quality of life will be assessed with the Stroke
 Impact Scale (SIS) controlling for depression using the Center for Epidemiologic Studies
 Depression (CES-D) scale. These clinical tests require approximately 1.5 hours to
 administer. Participants will also be encouraged to use their weaker hand and arm at
 home and during the weekends.

 2. Assistive repetitive motion (ARM) procedure: Patients will report to the Mellon Center
 at the Cleveland Clinic Foundation (CCF) around 8:00 AM each day and leave around 12:00
 PM. During their stay at the CCF they will be asked to wear an assistive device on their
 more impaired or affected upper extremity. This device will be placed snugly on their
 arm and wrist. The device has a small "air muscle" that when activated will slowly lift
 their fingers and wrist from your resting wrist position. This device is classified as a
 non-significant risk device by the FDA (see attached letter dated 1-15-05). The patient
 should not experience any pain or discomfort during this stretching activity. If they do
 experience any pain or discomfort they can activate a stop switch located on the control
 box with their unimpaired hand. The SIS, CES-D WMFT and FMA will be administered
 immediately before and after the training period and two months after completion of the
 training.

 3. RTP + ARM Procedure: Patients will report to the Mellon Center at the Cleveland Clinic
 Foundation (CCF) around 8:00 AM each day and leave around 12:00 PM. During their stay at
 the CCF they will be asked to wear an assistive device on their more impaired or
 affected upper extremity for two hours. This device will be placed snugly on their arm
 and wrist. The device has a small "air muscle" that when activated will slowly lift the
 fingers and wrist from a resting wrist position. They should not experience any pain or
 discomfort during this stretching activity. If they experience any pain or discomfort
 they can activate a stop switch located on the control box with the unimpaired hand.
 After completion of the two hour ARM intervention they will participate in two hours of
 RTP therapy. During this time they will engage in a series of activities that are
 planned for them to use the weaker or more impaired hand and arm. The SIS, CES-D WMFT
 and FMA will be administered immediately before and after the training period and two
 months after completion of the training.

 The results from this project will provide valuable data as a pre-requisite for submission of
 a multi-year R01 randomized clinical trial to determine the clinical efficacy of using an
 assistive device, such as the ARM, as an adjunct to RTP. This project has the potential to
 increase the availability of effective rehabilitation techniques to patients with stroke.

 Inclusion criteria Patients will not be excluded because of somatosensory deficits or the
 nature of previous physical interventions. We will not randomize patients on the basis of
 side of stroke or hand dominance but will undertake secondary data analyses examining these
 variables. In past applications of one form of RTP, CI therapy, to chronic stroke patients in
 the laboratories of Taub and Miltner, there were no significant differences in treatment
 effects for patients with right and left-sided strokes. In previous evaluations of CI
 therapy, Taub did not find any difference in outcomes among the small percentage of patients
 with pre-morbid left dominance. Therefore, there is no reason to exclude these patients from
 participation. We believe that the motivation to improve use of an affected pre-stroke
 non-dominant upper extremity is sufficiently strong to support profound improvement from
 treating that limb as well as from treating the dominant limb. Distributions of dominance and
 hand preference have been acquired from patients meeting eligibility criteria in 1998 at
 several sites for determining participation of sites for the EXCITE trial and side of
 cerebral pathology showed remarkably equal left-right distribution.

 Exclusion criteria

 1. a score of less than 24 on the Folstein Mini-Mental State Examination or a score of 36
 or below on the Token Test of the Multilingual Aphasia Examination

 2. a first stroke less than 3 months or more than 9 months prior to the initiation of
 therapy

 3. less than 18 years old

 4. clinical judgment of excessive frailty or lack of stamina (e.g., cannot attend to
 instructions, stay awake, engage in functional activities, etc.)

 5. serious uncontrolled medical conditions

 6. excessive pain in any joint of the more affected extremity that could limit ability to
 cooperate with the intervention, as judged by the examining clinician

 7. passive range of motion less than 45 degrees for: abduction, flexion or external
 rotation at shoulder, or pronation of forearm; or greater than 30 degrees flexion
 contracture at any finger joint (patients who pass the motor criteria specified above do
 not tend to have the type of pain or limitation of movement that would exclude them from
 treatment)

 8. unable to stand independently for 2 min., transfer independently to and from the toilet
 or perform sit-to-stand

 9. current participation in other pharmacological or physical intervention studies, or have
 received injections of anti-spasticity drugs into upper extremity musculature within the
 past 3 months, or wish to have drugs injected in the foreseeable future

 10. receiving any anti-spasticity drugs orally at the time of expected participation

 11. received phenol injections less than 12 months prior to receiving therapy

 12. contemplating a move from proximity to the treatment site in less than 1 year from the
 randomization date. Prospective patients who qualify but who have profound postural
 instability will undergo the intervention while walking with contact guarding or, when
 feasible, using their leg(s) and more involved arm to propel a wheelchair.
Inclusion criteria Patients will not be excluded because of somatosensory deficits or the
 nature of previous physical interventions. We will not randomize patients on the basis of
 side of stroke or hand dominance but will undertake secondary data analyses examining these
 variables. In past applications of one form of RTP, CI therapy, to chronic stroke patients
 in the laboratories of Taub and Miltner, there were no significant differences in treatment
 effects for patients with right and left-sided strokes. In previous evaluations of CI
 therapy, Taub did not find any difference in outcomes among the small percentage of
 patients with pre-morbid left dominance. Therefore, there is no reason to exclude these
 patients from participation. We believe that the motivation to improve use of an affected
 pre-stroke non-dominant upper extremity is sufficiently strong to support profound
 improvement from treating that limb as well as from treating the dominant limb.
 Distributions of dominance and hand preference have been acquired from patients meeting
 eligibility criteria in 1998 at several sites for determining participation of sites for
 the EXCITE trial and side of cerebral pathology showed remarkably equal left-right
 distribution.

 Exclusion criteria

 1. a score of less than 24 on the Folstein Mini-Mental State Examination or a score of 36
 or below on the Token Test of the Multilingual Aphasia Examination

 2. a first stroke less than 3 months or more than 9 months prior to the initiation of
 therapy

 3. less than 18 years old

 4. clinical judgment of excessive frailty or lack of stamina (e.g., cannot attend to
 instructions, stay awake, engage in functional activities, etc.)

 5. serious uncontrolled medical conditions

 6. excessive pain in any joint of the more affected extremity that could limit ability to
 cooperate with the intervention, as judged by the examining clinician

 7. passive range of motion less than 45 degrees for: abduction, flexion or external
 rotation at shoulder, or pronation of forearm; or greater than 30 degrees flexion
 contracture at any finger joint (patients who pass the motor criteria specified above
 do not tend to have the type of pain or limitation of movement that would exclude them
 from treatment)

 8. unable to stand independently for 2 min., transfer independently to and from the
 toilet or perform sit-to-stand

 9. current participation in other pharmacological or physical intervention studies, or
 have received injections of anti-spasticity drugs into upper extremity musculature
 within the past 3 months, or wish to have drugs injected in the foreseeable future

 10. receiving any anti-spasticity drugs orally at the time of expected participation

 11. received phenol injections less than 12 months prior to receiving therapy

 12. contemplating a move from proximity to the treatment site in less than 1 year from the
 randomization date. Prospective patients who qualify but who have profound postural
 instability will undergo the intervention while walking with contact guarding or, when
 feasible, using their leg(s) and more involved arm to propel a wheelchair.